ClinicalTrials.gg
CompletedNCT02927769CheckMate 744Updated Feb 10, 2025Results posted

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

A Phase 2 interventional study of Nivolumab and brentuximab vedotin in Hodgkin Disease, sponsored by Bristol-Myers Squibb. Completed at 79 sites in 11 countries. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
5 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.

Enrollment
21st of 52
72 · median 52
Started
2017
with 8 others
Phase 2
33 of 52
12 open now
Registered
9th of 52
by date
Lead sponsor
5 of 52
Bristol-Myers Squibb

Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 21st largest by enrollment, is one of 9 that started in 2017, is one of 33 in phase 2, and was the 9th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 161 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 134 Hodgkin Disease studies recruiting now, 71 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 5 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing nivolumab in Hodgkin Disease, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

03

Conditions studied

  • Hodgkin Disease

Browse trials for

04

Who can participate

Ages eligible
5 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Classic Hodgkin Lymphoma (cHL),
  • Minimal limitation on activities of daily living as measured by ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
  • One prior anti-cancer therapy that did not work

Exclusion criteria

Exclusion Criteria:

  • Active, known, or suspected disease or infection
  • Active cerebral/meningeal disease related to the underlying
  • More than one line of anti-cancer therapy or no treatment at all
  • Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
  • Prior treatment with any drug that targets T cell co-stimulation pathways (such as )

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Nivolumab + brentuximab vedotin

    Biological: Nivolumab · Biological: brentuximab vedotin

  • Experimental
    brentuximab vedotin + bendamustine

    Biological: brentuximab vedotin · Biological: bendamustine

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1

    The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who stopped study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method

    Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).

  2. Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1

    Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.

    Time frame: At 3 years post first dose of study therapy

  3. Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2

    The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method

    Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)

Secondary outcomes

  1. Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR)

    Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Participants who came off early for toxicity without CMR or PMR were evaluable.

    Time frame: From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks).

  2. Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR)

    Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by BICR or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy for R2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.

    Time frame: At 3 years post first dose of study therapy

  3. Duration of Response (DOR) by Blinded Independent Centralized Review (BICR)

    Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates

    Time frame: From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months)

  4. Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1

    The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who come off early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method

    Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).

  5. Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1

    Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.

    Time frame: At 3 years post first dose of study therapy

  6. Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2

    The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method.

    Time frame: From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)

  7. Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator

    Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieve a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline Participants who came off early for toxicity without CMR or PMR were evaluable.

    Time frame: From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks).

  8. Progression Free Survival (PFS) Rate at 3 Years by Investigator

    Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by investigator or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were be censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy forR2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.

    Time frame: At 3 years post first dose

  9. Duration of Response (DOR) by Investigator

    Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, the DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates.

    Time frame: From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months)

  10. The Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months).

  11. The Number of Participants With Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event.

    Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)

  12. The Number of Participants With Abnormal Laboratory Values for Specific Thyroid Tests

    The Number of Participants with Abnormal Laboratory Values for Specific Thyroid Tests.

    Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)

  13. The Number of Participants With Abnormal Laboratory Values for Liver Tests

    The Number of Participants with Abnormal Laboratory Values for Liver Tests.

    Time frame: From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)

  14. Number of Participants With Abnormal Vital Signs Reported as Adverse Events

    Temperature, blood pressure, and heart rate abnormalities reported as adverse events.

    Time frame: From first dose to 100 days after last dose of study therapy (assessed for an average of 7 months up until a maximum of 10 months).

07

Results

Posted Feb 10, 2025

Participant flow

Induction Phase
Participant flow — Induction Phase
MilestoneCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Started2844
Completed2742
Not completed12
Withdrew: Study drug toxicity11
Withdrew: Disease progression01
Consolidation Phase
Participant flow — Consolidation Phase
MilestoneCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Started2232
Completed2232
Not completed00
Intensification Phase
Participant flow — Intensification Phase
MilestoneCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Started611
Completed511
Not completed10
Withdrew: Study drug toxicity10

Outcome measures

PrimaryComplete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1

The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who stopped study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method

Time frame:
From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).
Reported as:
Number · Percent of participants
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 1
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Blinded Independent Centralized Review (BICR) - Cohort 192.9 (79.2 to 98.7)
PrimaryEvent-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1

Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.

Time frame:
At 3 years post first dose of study therapy
Reported as:
Number · Percent of participants
Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 1
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse
Event-free Survival (EFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR) - Cohort 187.5 (70.6 to 95.0)
PrimaryComplete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2

The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method

Time frame:
From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)
Reported as:
Number · Percent of participants
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 2
Percent of participantsCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Blinded Independent Centralized Review (BICR) - Cohort 288.6 (77.6 to 95.4)
SecondaryOverall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR)

Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the BICR, achieved a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Participants who came off early for toxicity without CMR or PMR were evaluable.

Time frame:
From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks).
Reported as:
Number · Percent of participants
Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR)
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Blinded Independent Centralized Review (BICR)96.4 (84.1 to 99.8)93.2 (83.3 to 98.1)
SecondaryProgression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR)

Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by BICR or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy for R2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.

Time frame:
At 3 years post first dose of study therapy
Reported as:
Number · Percent of participants
Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR)
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Progression Free Survival (PFS) Rate at 3 Years by Blinded Independent Centralized Review (BICR)95.2 (77.7 to 99.1)91.1 (78.4 to 96.5)
SecondaryDuration of Response (DOR) by Blinded Independent Centralized Review (BICR)

Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response (PMR): * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates

Time frame:
From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months)
Reported as:
Median · Months
Duration of Response (DOR) by Blinded Independent Centralized Review (BICR)
MonthsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Duration of Response (DOR) by Blinded Independent Centralized Review (BICR)NA (NA to NA)NA (NA to NA)
SecondaryComplete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1

The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who come off early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method

Time frame:
From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks).
Reported as:
Number · Percent of participants
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 1
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse
Complete Metabolic Response (CMR) Rate at Any Time Prior to Radiation Therapy by Investigator - Cohort 189.3 (74.6 to 97.0)
SecondaryEvent-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1

Event Free Survival (EFS) is the time from the first treatment to the earliest occurrence of composite events including: Disease progression (PD), Failure to achieve complete metabolic response (CMR) after 4 cycles of N+Bv and 2 cycles of Bv+B, Secondary malignancy, Death . PD : Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease CMR: Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale New lesions: No Bone marrow: No FDG-avid disease Participants without an "event" were censored at the last tumor assessment. Those who started subsequent anticancer therapy without a prior "event" were censored at the last tumor assessment prior to or upon starting subsequent therapy. Based on Kaplan-Meier Estimates.

Time frame:
At 3 years post first dose of study therapy
Reported as:
Number · Percent of participants
Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 1
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse
Event-free Survival (EFS) Rate at 3 Years by Investigator - Cohort 188.5 (72.8 to 95.4)
SecondaryComplete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2

The complete metabolic response (CMR) rate is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieved best response of CMR. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Participants who came off study treatment early for toxicity without a CMR were evaluable. Confidence interval is based on the Clopper and Pearson method.

Time frame:
From first dose to complete metabolic response or the completion of six cycles of therapy (up to approximately 18 weeks)
Reported as:
Number · Percent of participants
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 2
Percent of participantsCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Complete Metabolic Response (CMR) Rate at Any Time Prior to High Dose Chemotherapy Followed by Autologous Stem Cell Treatment (HDCT/ASCT) by Investigator - Cohort 286.4 (74.8 to 93.9)
SecondaryOverall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator

Overall response rate (ORR) is defined as the percent of all response-evaluable participants who, assessed by the investigator, achieve a best response of complete metabolic response (CMR) or partial metabolic response (PMR). Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline Participants who came off early for toxicity without CMR or PMR were evaluable.

Time frame:
From first dose to PMR or CMR within 4 cycles of therapy, or the completion of four cycles of therapy (N+Bv x4) (up to approximately 12 weeks).
Reported as:
Number · Percent of participants
Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Overall Response Rate (ORR) Following 4 Cycles of Nivolumab + Brentuximab Vedotin Treatment by Investigator100.0 (89.9 to 100.0)90.9 (80.4 to 96.8)
SecondaryProgression Free Survival (PFS) Rate at 3 Years by Investigator

Progression Free Survival (PFS) is the time from the date of first treatment to the date of first documented disease progression by investigator or death. Progressive Disease (PD): Lymph Nodes and Lesions: new growth or increase of \>= 50% in size from nadir. New or growing lesions outside the lymph nodes. Spleen: Significant increase in spleen size, either from a previously enlarged state or from normal size. New Lesions: Yes Bone Marrow: New or returning FDG-avid disease. Participants who neither progressed nor died were be censored at the last adequate tumor assessment. Participants who started subsequent anticancer therapy (that is not part of high dose chemotherapy followed by autologous stem cell transplant (HDCT/ASCT) Consolidation Therapy forR2 Cohort) without a prior reported progression or death were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Based on Kaplan-Meier Estimates.

Time frame:
At 3 years post first dose
Reported as:
Number · Percent of participants
Progression Free Survival (PFS) Rate at 3 Years by Investigator
Percent of participantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Progression Free Survival (PFS) Rate at 3 Years by Investigator95.8 (80.2 to 99.2)88.1 (74.8 to 94.6)
SecondaryDuration of Response (DOR) by Investigator

Duration of response (DOR) is the time from first complete metabolic response or partial metabolic response (CMR or PMR) to event free survival EFS (Cohort 1)/progression free survival PFS (Cohort 2) event. For participants with no event, the DOR was censored on the date of last tumor assessment. Participants who started subsequent anticancer therapy (not part of high-dose chemotherapy followed by autologous stem cell transplant HDCT/ASCT) without a prior reported EFS/PFS event were censored at the last tumor assessment prior to initiation of the subsequent anticancer therapy. Complete metabolic response (CMR): * Lymph nodes/extralymphatic sites: Score 1, 2, 3 with/without residual mass on 5-point scale * New lesions: No * Bone marrow: No FDG-avid disease Partial metabolic response: * Lymph nodes/extralymphatic: Score 4 or 5, reduced uptake from baseline * New lesions: None * Bone marrow: Residual uptake higher than normal, reduced from baseline. Based on Kaplan-Meier estimates.

Time frame:
From first dose until disease progression, start of subsequent anti-cancer therapy, or or death due to any cause (up to approximately 86 months)
Reported as:
Median · Months
Duration of Response (DOR) by Investigator
MonthsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Duration of Response (DOR) by InvestigatorNA (NA to NA)NA (NA to NA)
SecondaryThe Number of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

Time frame:
From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months).
Reported as:
Count of participants · Participants
The Number of Participants With Adverse Events (AEs)
ParticipantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
The Number of Participants With Adverse Events (AEs)2642
SecondaryThe Number of Participants With Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event.

Time frame:
From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)
Reported as:
Count of participants · Participants
The Number of Participants With Serious Adverse Events (SAEs)
ParticipantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
The Number of Participants With Serious Adverse Events (SAEs)89
SecondaryThe Number of Participants With Abnormal Laboratory Values for Specific Thyroid Tests

The Number of Participants with Abnormal Laboratory Values for Specific Thyroid Tests.

Time frame:
From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)
Reported as:
Count of participants · Participants
The Number of Participants With Abnormal Laboratory Values for Specific Thyroid Tests
ParticipantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
TSH > ULN68
TSH > ULN WITH TSH <= ULN AT BASELINE54
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN10
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN45
TSH > ULN WITH FT3/FT4 TEST MISSING13
TSH < LLN41
TSH <LLN WITH TSH >= LLN AT BASELINE41
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN31
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN10
TSH < LLN WITH FT3/FT4 TEST MISSING00
SecondaryThe Number of Participants With Abnormal Laboratory Values for Liver Tests

The Number of Participants with Abnormal Laboratory Values for Liver Tests.

Time frame:
From first dose to 30 days post last dose (an average of 4 months up until a maximum of 7 months)
Reported as:
Count of participants · Participants
The Number of Participants With Abnormal Laboratory Values for Liver Tests
ParticipantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
ALT OR AST > 3XULN85
ALT OR AST> 5XULN31
ALT OR AST> 10XULN00
ALT OR AST > 20XULN00
TOTAL BILIRUBIN > 2XULN10
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY00
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS00
SecondaryNumber of Participants With Abnormal Vital Signs Reported as Adverse Events

Temperature, blood pressure, and heart rate abnormalities reported as adverse events.

Time frame:
From first dose to 100 days after last dose of study therapy (assessed for an average of 7 months up until a maximum of 10 months).
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as Adverse Events
ParticipantsCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse
Pyrexia723
Tachycardia21
Sinus Bradycardia02
Hypertension04
Hypotension06
Orthostatic hypotension01

Adverse events

Collected over Participants were assessed for All-Cause Mortality from first dose until study completion (assessed up to approximately 86 months). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (assessed for an average of 7 months up until a maximum of 10 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv)0/22 (0%)6/22 (27.3%)18/22 (81.8%)
Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B)0/6 (0%)3/6 (50%)6/6 (100%)
Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)0/33 (0%)11/33 (33.3%)33/33 (100%)
Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B)1/11 (9.1%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv)Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B)Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B)
PyrexiaGeneral disorders2/223/63/331/11
Otitis mediaInfections and infestations0/221/60/330/11
Infusion related reactionInjury, poisoning and procedural complications0/221/61/330/11
Pain in extremityMusculoskeletal and connective tissue disorders0/221/60/330/11
Acute kidney injuryRenal and urinary disorders0/221/60/330/11
UrticariaSkin and subcutaneous tissue disorders0/221/60/330/11
StomatitisGastrointestinal disorders0/220/60/331/11
Chest painGeneral disorders0/220/60/331/11
HypersensitivityImmune system disorders1/220/61/331/11
HypoxiaRespiratory, thoracic and mediastinal disorders0/220/60/331/11
Most frequent other events
Showing 10 of 120
Most frequent other events
EventCohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv)Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk Relapse (Nivo + Bv) + (Bv + B)Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)Cohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk Relapse (Nivo + Bv)+(Bv + B)
NauseaGastrointestinal disorders9/223/619/3311/11
VomitingGastrointestinal disorders2/223/67/336/11
PyrexiaGeneral disorders1/222/617/335/11
Mucosal inflammationGeneral disorders1/220/610/335/11
Infusion related reactionInjury, poisoning and procedural complications4/221/64/335/11
HeadacheNervous system disorders10/222/66/334/11
DiarrhoeaGastrointestinal disorders5/221/613/334/11
Febrile neutropeniaBlood and lymphatic system disorders0/220/65/334/11
Abdominal painGastrointestinal disorders1/220/69/334/11
RashSkin and subcutaneous tissue disorders0/220/63/334/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk RelapseTotal
Mean17.0 ± 4.316.2 ± 3.716.5 ± 4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk RelapseTotal
Female181533
Male102939
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk RelapseTotal
Hispanic or Latino314
Not Hispanic or Latino82028
Unknown or Not Reported172340
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Relapsed/Refractory Classic Hodgkin Lymphoma - Low Risk RelapseCohort 2: Relapsed/Refractory Classic Hodgkin Lymphoma - Standard Risk RelapseTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander011
Black or African American112
White254166
More than one race000
Unknown or Not Reported112
08

Study locations

79 sites
  • Children's Hospital of Alabama
    Birmingham, Alabama 35233, United States
  • Phoenix Children'S Hospital
    Phoenix, Arizona 85016, United States
  • Loma Linda University Cancer Center
    Loma Linda, California 92350, United States
  • Valley Children's Hospital
    Madera, California 93636, United States
  • Children'S Hospital & Research Center At Oakland
    Oakland, California 94609, United States
  • Children'S Hospital Of Orange County
    Orange, California 92868, United States
  • Lucile Packard Children'S Research Hospital/Stanford Univ
    Palo Alto, California 94304, United States
  • Local Institution - 0091
    San Diego, California 92109, United States
  • Childrens Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Smilow Cancer Hospital At Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
  • Nemours / A. I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children'S National Medical Center
    Washington, District of Columbia 20010, United States
  • Local Institution - 0062
    Jacksonville, Florida 32207, United States
  • Local Institution - 0069
    Saint Petersburg, Florida 33701, United States
  • Children's Healthcare Of Atlanta
    Atlanta, Georgia 30322, United States
  • University Of Iowa
    Iowa City, Iowa 52242, United States
  • Local Institution - 0070
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute.
    Boston, Massachusetts 02215, United States
  • Local Institution - 0097
    Detroit, Michigan 48201, United States
  • Local Institution - 0049
    Jackson, Mississippi 39216, United States
  • Local Institution - 0085
    Kansas City, Missouri 64108, United States
  • Washington University School Of Medicine
    Saint Louis, Missouri 63110, United States
  • Nevada Cancer Research Foundation
    Las Vegas, Nevada 89135, United States
  • Local Institution - 0067
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0047
    New Brunswick, New Jersey 08903, United States
  • Local Institution - 0068
    Buffalo, New York 14263, United States
  • Local Institution
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Cincinnati Children'S Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Local Institution - 0089
    Columbus, Ohio 43205, United States
  • University Of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 0090
    Hershey, Pennsylvania 17033-0850, United States
  • Childrens Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Childrens Hospital Of Pittsburgh Of Upmc
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University
    Nashville, Tennessee 37232-6310, United States
  • Local Institution - 0042
    Austin, Texas 78723, United States
  • Local Institution - 0071
    Dallas, Texas 75235, United States
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Children'S Hosp-Kings Daughter
    Norfolk, Virginia 23507-1910, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Local Institution - 0048
    Seattle, Washington 98105, United States
  • Local Institution - 0065
    Milwaukee, Wisconsin 53226, United States
  • Local Institution
    Calgary, Alberta T3B 6A8, Canada
  • Local Institution - 0092
    Toronto, Ontario M5G 1X8, Canada
  • The Montreal Children's Hospital of the MUHC
    Montreal, Quebec H4A 3J1, Canada
  • Klinika detske hematologie a onkologie
    Praha 5, 150 06, Czechia
  • Local Institution - 0034
    Vandoeuvre lès Nancy, Meurthe-et-Moselle 54511, France
  • Local Institution - 0030
    Lille cedex, 59037, France
  • Local Institution - 0029
    Lyon Cedex 08, 69008, France
  • Local Institution - 0032
    Marseille, 13011, France
  • Local Institution - 0028
    Nantes, 44093, France
  • Local Institution - 0031
    Paris, 75012, France
  • Local Institution - 0026
    Paris, 75019, France
  • Local Institution - 0033
    Toulouse cedex 9, 31059, France
  • Local Institution - 0027
    Villejuif, 94805, France
  • Local Institution - 0056
    Berlin, 13353, Germany
  • Local Institution - 0055
    Giessen, 35392, Germany
  • Local Institution - 0057
    Hannover, 30625, Germany
  • Local Institution - 0102
    Muenchen, 80337, Germany
  • Local Institution - 0017
    Dublin, Dublin 8, Ireland
  • Local Institution - 0024
    Aviano (PN), 33081, Italy
  • Local Institution - 0020
    Bologna, 40138, Italy
  • Local Institution - 0021
    Genova, 16147, Italy
  • Local Institution - 0019
    Monza (mb), 20900, Italy
  • Local Institution - 0023
    Napoli, 80123, Italy
  • Local Institution - 0022
    Roma, 00161, Italy
  • Local Institution - 0001
    Rotterdam, 3015 CN, Netherlands
  • Local Institution - 0006
    Utrecht, 3584 CS, Netherlands
  • Local Institution
    Gdansk, 80-952, Poland
  • Local Institution
    Krakow, 30-663, Poland
  • Local Institution - 0082
    Barcelona, 08950, Spain
  • Local Institution - 0084
    Madrid, 28009, Spain
  • Local Institution - 0035
    Leeds, North Yorkshire LS1 3EX, United Kingdom
  • Local Institution
    Leeds, Yorkshire LS9 7TF, United Kingdom
  • Local Institution
    Birmingham, B15 2TH, United Kingdom
  • Local Institution
    Glasgow, G51 4TF, United Kingdom
  • Local Institution - 0002
    London, NW1 2BU, United Kingdom
  • Local Institution - 0012
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in May 2024, 86 months.

Results were first posted in Feb 2025, 8 months after primary completion.

Of 203 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 86 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2016
First posted
Oct 7, 2016
StartActual
Mar 28, 2017
Primary completionActual
May 28, 2024
CompletionActual
May 28, 2024
Results first posted
Feb 10, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02927769
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 7, 2016
Start date
Mar 28, 2017
Primary completion
May 28, 2024
Completion
May 28, 2024
Results posted
Feb 10, 2025
Last update
Feb 10, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Bendamustine

Start the discussion